Di(cyanate Ester) Networks Based on Alternative Fluorinated Bisphenols with Extremely Low Water Uptake

A new polycyanurate network exhibiting extremely low moisture uptake has been produced via the treatment of perfluorocyclobutane-containing Bisphenol T with cyanogen bromide and subsequent thermal cyclotrimerization. The water uptake, at 0.56 ± 0.10% after immersion in water at 85 °C for 96 h, represents some of the most promising moisture resistance observed to date in polycyanurate networks. This excellent performance derives from a near optimal value of the glass transition at 190 °C at full cure. Superior dielectric loss characteristics compared to commercial polycyanurate networks based on Bisphenol E were also observed. Polycyanurate networks derived from this new monomer appear particularly well-suited for applications such as radomes and spacecrafts where polycyanurates are already widely recognized as providing outstanding properties

Di(cyanate Ester) Networks Based on Alternative Fluorinated Bisphenols with Extremely Low Water Uptake

A new polycyanurate network exhibiting extremely low moisture uptake has been produced via the treatment of perfluorocyclobutane-containing Bisphenol T with cyanogen bromide and subsequent thermal cyclotrimerization. The water uptake, at 0.56 ± 0.10% after immersion in water at 85 °C for 96 h, represents some of the most promising moisture resistance observed to date in polycyanurate networks. This excellent performance derives from a near optimal value of the glass transition at 190 °C at full cure. Superior dielectric loss characteristics compared to commercial polycyanurate networks based on Bisphenol E were also observed. Polycyanurate networks derived from this new monomer appear particularly well-suited for applications such as radomes and spacecrafts where polycyanurates are already widely recognized as providing outstanding properties

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial

IMPORTANCE: Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety. OBJECTIVE: To assess safety and efficacy of roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis affecting the scalp, face, and/or trunk. DESIGN, SETTING, AND PARTICIPANTS: This multicenter (24 sites in the US and Canada) phase 2a, parallel group, double-blind, vehicle-controlled clinical trial was conducted between November 12, 2019, and August 21, 2020. Participants were adult (aged ≥18 years) patients with a clinical diagnosis of seborrheic dermatitis for a 3-month or longer duration and Investigator Global Assessment (IGA) score of 3 or greater (at least moderate), affecting 20% or less body surface area, including scalp, face, trunk, and/or intertriginous areas. Data analysis was performed from September to October 2020. INTERVENTIONS: Once-daily roflumilast foam, 0.3% (n = 154), or vehicle foam (n = 72) for 8 weeks. MAIN OUTCOMES AND MEASURES: The main outcome was IGA success, defined as achievement of IGA score of clear or almost clear plus 2-grade improvement from baseline, at week 8. Secondary outcomes included IGA success at weeks 2 and 4; achievement of erythema score of 0 or 1 plus 2-grade improvement from baseline at weeks 2, 4, and 8; achievement of scaling score of 0 or 1 plus 2-grade improvement from baseline at weeks 2, 4, and 8; change in Worst Itch Numeric Rating Scale (WI-NRS) score from baseline; and WI-NRS success, defined as achievement of 4-point or greater WI-NRS score improvement in patients with baseline WI-NRS score of 4 or greater. Safety and tolerability were also assessed. RESULTS: A total of 226 patients (mean [SD] age, 44.9 [16.8] years; 116 men, 110 women) were randomized to roflumilast foam (n = 154) or vehicle foam (n = 72). At week 8, 104 (73.8%) roflumilast-treated patients achieved IGA success compared with 27 (40.9%) in the vehicle group (P \u3c .001). Roflumilast-treated patients had statistically significantly higher rates of IGA success vs vehicle at week 2, the first time point assessed. Mean (SD) reductions (improvements) on the WI-NRS at week 8 were 59.3% (52.5%) vs 36.6% (42.2%) in the roflumilast and vehicle groups, respectively (P \u3c .001). Roflumilast was well tolerated, with the rate of adverse events similar to that of the vehicle foam. CONCLUSIONS AND RELEVANCE: The results from this phase 2a randomized clinical trial of once-daily roflumilast foam, 0.3%, demonstrated favorable efficacy, safety, and local tolerability in the treatment of erythema, scaling, and itch caused by seborrheic dermatitis, supporting further investigation as a nonsteroidal topical treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04091646